Vectura appoints Director of Investor Relations and Corporate Communications
01 May 2007
Vectura Group plc Appoints Julia Wilson as Director of Investor Relations and Corporate Communications
Chippenham, UK – 1 May , 2007: Vectura Group plc (LSE: VEC) announces the appointment of Ms Julia Wilson to the new position of Director of Investor Relations and Corporate Communications.
Julia has over twelve years experience in the biotechnology industry and was most recently Head of Corporate Communications at Vernalis Plc. Before joining Vernalis Julia held communications positions with Merlin Biosciences Limited, Millennium Pharmaceuticals Ltd and Cambridge Discovery Chemistry.
Dr. Chris Blackwell, Chief Executive of Vectura Group plc, said “In her new role we believe that Julia’s wide experience in the pharmaceutical industry and her track record in investor relations will be of great assistance in our forthcoming move to the main list and all our future communications. I am delighted to welcome Julia to Vectura.”
Enquiries:
Vectura Group plc Tel: + 44 (0) 1249 667700
Chris Blackwell, Chief Executive
Anne Hyland, Chief Financial Officer
About Vectura
Vectura’s principal focus is the development of a range of inhaled drugs for the treatment of both lung diseases and other conditions where optimised delivery via the lungs can provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.
The Company has development collaborations with Boehringer Ingelheim, Novartis, GSK and Chiesi as well as with other non-disclosed pharmaceutical companies. The acquisition of Innovata in January 2007 added further development and licensing partnerships including, Baxter, UCB and Otsuka as well as expanding its range of inhalation technologies and development programmes. For further information, please visit Vectura’s website at www.vectura.com
